Business context and reporting period
Filing identity differs from request: the supplied 10-K is for Cactus Ventures, Inc., not Actinium Pharmaceuticals, Inc. It covers the fiscal year ended December 31, 2011, with 2010 comparisons; it is not a quarterly filing. Cactus describes itself as a shell company seeking a merger or acquisition. It reports no active negotiations or identified target as of the filing.
Financial results and liquidity
- Revenue: $0 in both 2011 and 2010. The company had no operating business or revenue-generating products.
- Net income: $10,289 in 2011 versus $1,674 in 2010. Results included a $25,000 gain from a forfeited, non-refundable acquisition deposit in 2011, compared with $35,000 in 2010.
- Operating costs and interest: The financial statements report operating expenses of $9,952 in 2011 and $26,053 in 2010, and interest expense of $4,759 and $6,439, respectively. No gross margin is meaningful because sales were zero.
- Cash flow: Operating cash flow was positive $539 in 2011, offset by $539 of net financing cash outflow; cash remained $150 at year-end. In 2010, operating cash flow was $7,835 and financing cash outflow was $9,807; cash declined from $2,122 to $150.
- Assets and liabilities: Year-end assets were $150, all cash. Total liabilities were $84,479, including $58,168 in related-party notes and $26,005 in accrued interest. Shareholders’ deficit was $84,329; the filing reports a $26,161 working-capital deficiency.
- Funding: Management estimated approximately $20,000 of expenses over the next 12 months and expected the president to continue advancing funds, but there was no commitment to do so. Related-party notes were extended from December 31, 2011 to December 31, 2012; stated interest rates were 8% or 12%, depending on when advances were made.
Changes, outlook, and risks
Compared with 2010, reported net income increased, while operating expenses and interest expense decreased. The deposit-forfeiture gain fell by $10,000. These gains, rather than operating revenue, drove reported profitability. The company anticipated continued losses from reporting and acquisition-search costs until a business combination, and said it might remain loss-making after a transaction.
The independent auditor highlighted substantial doubt about the company’s ability to continue as a going concern, citing accumulated losses, negative working capital, and shareholders’ deficit. Continued operations depend on related parties funding the company. Management warned that any acquisition could require substantial share issuance and dilute existing holders; there is no assurance a suitable transaction will be found or completed. Other disclosed risks include limited management time and resources, competition for acquisition targets, penny-stock trading restrictions, and very limited or nonexistent market liquidity. The company reported no pending legal proceedings and no off-balance-sheet arrangements with a material effect.
Important facts to verify
- Confirm the issuer and period: the source is Cactus Ventures’ 2011 annual report, not an Actinium Pharmaceuticals filing or a 2011 Q4 report.
- Reconcile the MD&A’s expense description and figures with the audited income statement; the MD&A describes $20,241 of expenses, while the statements show $9,952 of operating expenses plus other income and expenses.
- Verify the reported per-share figure: the income statement shows positive net income but labels loss per common share as $0.01 for both years.
- Reconcile accrued interest disclosures: the balance sheet and notes report $26,005 for 2011, while related-party discussion elsewhere gives $25,970.
- Assess whether related-party advances will continue and whether the company can meet obligations and fund operations without a completed transaction.
- Evaluate the $25,000 deposit-forfeiture gain and the very limited trading market when assessing the sustainability of reported earnings and share liquidity.